165 related articles for article (PubMed ID: 24535626)
21. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
[TBL] [Abstract][Full Text] [Related]
22. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
[TBL] [Abstract][Full Text] [Related]
23. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial.
Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM;
JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355
[TBL] [Abstract][Full Text] [Related]
24. Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.
Riordan A; Judd A; Boyd K; Cliff D; Doerholt K; Lyall H; Menson E; Butler K; Gibb D;
Pediatr Infect Dis J; 2009 Mar; 28(3):204-9. PubMed ID: 19209091
[TBL] [Abstract][Full Text] [Related]
25. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
28. Lack of a significant drug interaction between raltegravir and tenofovir.
Wenning LA; Friedman EJ; Kost JT; Breidinger SA; Stek JE; Lasseter KC; Gottesdiener KM; Chen J; Teppler H; Wagner JA; Stone JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Sep; 52(9):3253-8. PubMed ID: 18625763
[TBL] [Abstract][Full Text] [Related]
29. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
30. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.
Menezes CN; Duarte R; Dickens C; Dix-Peek T; Van Amsterdam D; John MA; Ive P; Maskew M; Macphail P; Fox MP; Raal F; Sanne I; Crowther NJ
HIV Med; 2013 Apr; 14(4):217-25. PubMed ID: 23036096
[TBL] [Abstract][Full Text] [Related]
31. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
Kinai E; Hanabusa H
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
[TBL] [Abstract][Full Text] [Related]
33. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Mandala J; Nanda K; Wang M; De Baetselier I; Deese J; Lombaard J; Owino F; Malahleha M; Manongi R; Taylor D; Van Damme L
BMC Pharmacol Toxicol; 2014 Dec; 15():77. PubMed ID: 25539648
[TBL] [Abstract][Full Text] [Related]
34. Effects of vitamin D supplementation on FGF23: a randomized-controlled trial.
Trummer C; Schwetz V; Pandis M; Grübler MR; Verheyen N; Gaksch M; Zittermann A; März W; Aberer F; Steinkellner J; Friedl C; Brandenburg V; Voelkl J; Alesutan I; Obermayer-Pietsch B; Pieber TR; Tomaschitz A; Pilz S
Eur J Nutr; 2019 Mar; 58(2):697-703. PubMed ID: 29602956
[TBL] [Abstract][Full Text] [Related]
35. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
38. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
[TBL] [Abstract][Full Text] [Related]
39. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.
Cooper RD; Wiebe N; Smith N; Keiser P; Naicker S; Tonelli M
Clin Infect Dis; 2010 Sep; 51(5):496-505. PubMed ID: 20673002
[TBL] [Abstract][Full Text] [Related]
40. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
